Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S.

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance ...

The investigational combination xanomeline-trospium (KarXT) was effective and well tolerated in individuals with schizophrenia who were experiencing acute psychosis, according to the randomized ...

The stress of becoming homeless along with cannabis use may have triggered the first schizophrenic episode in a young man who ...

Sexuality for people with schizophrenia is still an area under research. Healthcare experts are aiming to understand psychotic disorders in relation to sexuality alongside a greater understanding ...

Psychotherapy and medications can help manage and reduce the effects of psychosis and schizophrenia symptoms. A person needs to continue with treatment even after recovering from an acute episode ...

for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti. Bysanti is a new chemical entity ...

The latest issues of three American Psychiatric Association journals, The American Journal of Psychiatry, Psychiatric Services and The American Journal of Psychotherapy  are now available online.

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute ...